Lung Cancer
Volume 47, Issue 1 , Pages 129-138 , January 2005

Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity

  • Chao-Hua Chiu

      Affiliations

    • Chest Department, Taipei Veterans General Hospital, No. 201 Section 2, Shih-Pai Road, Taipei 112, Taiwan, ROC
    • Department of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC
    • ,
  • Chun-Ming Tsai

      Affiliations

    • Chest Department, Taipei Veterans General Hospital, No. 201 Section 2, Shih-Pai Road, Taipei 112, Taiwan, ROC
    • Department of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC
    • Corresponding Author InformationCorresponding author. Tel.: +886 2 28757496; fax: +886 2 28760675.
    • ,
  • Yuh-Min Chen

      Affiliations

    • Chest Department, Taipei Veterans General Hospital, No. 201 Section 2, Shih-Pai Road, Taipei 112, Taiwan, ROC
    • Department of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC
    • ,
  • Shu-Chen Chiang

      Affiliations

    • Chest Department, Taipei Veterans General Hospital, No. 201 Section 2, Shih-Pai Road, Taipei 112, Taiwan, ROC
    • ,
  • Jia-Ling Liou

      Affiliations

    • Chest Department, Taipei Veterans General Hospital, No. 201 Section 2, Shih-Pai Road, Taipei 112, Taiwan, ROC
    • ,
  • Reury-Perng Perng

      Affiliations

    • Chest Department, Taipei Veterans General Hospital, No. 201 Section 2, Shih-Pai Road, Taipei 112, Taiwan, ROC
    • Department of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC

Received 16 February 2004 ,Revised 12 May 2004 ,Accepted 18 May 2004.

References 

  1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics. CA Cancer J. Clin. 2003;53:5–26
  2. Newman SJ, Hansen HH. Frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer. 1974;33:492–496
  3. Cox JD, Yesner RA. Adenocarcinoma of the lung: recent results from the Veterans Administration Lung Group. Am. Rev. Respir. Dis. 1979;120:1025–1029
  4. Ryan GF, Ball DL, Smith JG. Treatment of brain metastases from primary lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 1995;31:273–278
  5. Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer. 1986;58:832–839
  6. Rustin GJ, Newlands ES, Bagshawe KD, Begent RH, Crawford SM. Successful management of metastatic and primary germ cell tumors in the brain. Cancer. 1986;57:2108–2113
  7. Kristensen CA, Kristjansen PEG, Hansen HH. Systemic chemotherapy of brain metastases from small-cell lung cancer: a review. J. Clin. Oncol. 1992;10:1498–1502
  8. Minotti V, Crino L, Meacci ML, et al.  Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer. Lung Cancer. 1998;20:93–98
  9. Bernardo G, Cuzzoni Q, Strada MR, et al.  First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study. Cancer Invest. 2002;20:293–302
  10. Cortes J, Rodriguez J, Aramendia JM, et al.  Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology. 2003;64:28–35
  11. Fukuoka M, Yano S, Giaccone G, et al.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2003;21:2237–2246
  12. Kris MG, Natale RB, Herbst RS, et al.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290:2149–2158
  13. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899–909.
  14. Therasse P, Arbuck SG, Eisenhauer EA, et al.  New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 2000;92:205–216
  15. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–214
  16. Hollen PJ, Gralla RJ, Kris MG, Potanovich LM. Quality of life assessment in individuals with lung cancer: testing the lung cancer symptom scale (LCSS). Eur. J. Cancer. 1993;29A:S51–S58
  17. Ranson M, Hammond LA, Ferry D, et al.  ZD1839(‘Iressa’), a selective oral EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitor) is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J. Clin. Oncol. 2002;20:2240–2250
  18. Heimberger AB, Learn CA, Archer GE, et al.  Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa). Clin. Cancer Res. 2002;8:3496–3502
  19. Rich JN, Reardon DA, Peery T, et al.  Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol. 2004;22:133–142
  20. Iacono LC, Geyer JR, Kun LE, et al.  Pharmacokinetics of gefitinib in children with brain tumors. Proc. Am. Soc. Clin. Oncol. 2003;22:132a
  21. Villano JL, Mauer AM, Vokes EE. A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain. Ann. Oncol. 2003;14:656–658
  22. Cappuzzo F, Ardizzoni A, Soto-Parra H, et al.  Epidermal growth factor receptor targeted therapy by ZD1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer. 2003;41:227–231
  23. Cappuzzo F, Calandri C, Bartolini S, Crino L. ZD1839 in patients with brain metastases from non-small cell lung cancer (NSCLC): report of four cases. Br J Cancer. 2003;89:246–247
  24. Postmus PE, Smit EF. Chemotherapy for brain metastases of lung cancer: a review. Ann Oncol. 1999;10:753–759
  25. Katakami N, Okazaki M, Kinose D, et al.  A retrospective analysis of the outcome of patients (pts) in advanced recurrent adenocarcinoma of the lung who have received gefitinib after treatment of platinum-base regimen. Proc. Am. Soc. Clin. Oncol. 2003;22:666a
  26. Wong NS, Lim ST, Lim WT, Leong SS, Tan EH. ZD1839 is more effective in patients with non-small cell lung cancer (NSCLC) who were lifetime non-tobacco users. Proc. Am. Soc. Clin. Oncol. 2003;22:694a
  27. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Sci. Expr. [published online 29 April 2004].
  28. Inoue A, Saijo Y, Maemondo M, et al.  Severe acute interstitial pneumonia and gefitinib. Lancet. 2003;361:137–139
  29. Tamura K, Yamamoto N, Takeda K, et al.  Am epidemiological survey for interstitial lung disease induced by gefitinib in patients with advanced non-small cell lung cancer. West Japan Thoracic Oncology Group (WJTOG). Eur. J. Cancer Suppl. 2003;1(5):S21
  30. Cohen EEW, Rosen F, Stadler WM, et al.  Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2003;21:1980–1987
  31. Janne PA, Gurubhagavatula S, Lucca J, et al.  Clinical benefits in patients with advanced non-small-cell lung cancer treated with gefitinib (“Iressa”, ZD1839) in the compassionate use program. Lung Cancer. 2003;41(Suppl 2):S71
  32. Perez-Soler R, Chachoua A, Huberman M, et al.  Final results from a phase II study of erlotinib (Tarceva) monotherapy in patients with advanced non-small cell lung cancer following failure of platinum-based chemotherapy. Lung Cancer. 2003;41(Suppl 2):S246–S247
  33. Clark GM, Perez-Soler R, Siu L, Gordon A, Santabaabara P. Rash severity is predictive of increased survival with erlotinib HCl. Proc. Am. Soc. Clin. Oncol. 2003;22:196a
  34. Saltz L, Kies M, Abbruzzese L, et al.  The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc. Am. Soc. Clin. Oncol. 2003;22:204a
  35. Lynch T, Ranson M, Herbst R, et al.  Skin toxicity is not a clinical prognostic marker for tumor response to gefitinib (Iressa, ZD1839) in pre-treated patients with advanced non-small cell lung cancer. Clin. Cancer Res. 2003;9(Suppl 16):70
  36. Reynolds NJ, Talwar HS, Baldassare JJ, et al.  Differential induction of phosphatidylcholine hydrolysis, diacylglycerol formation and protein kinase C activation by epidermal growth factor and transforming growth factor-alpha in normal human skin fibroblasts and keratinocytes. Biochem. J. 1993;294:535–544

☆ Part of this study has been presented at the 10th World Conference on Lung Cancer, 10–14 August 2003, Vancouver, Canada.

PII: S0169-5002(04)00258-2

doi: 10.1016/j.lungcan.2004.05.014

Lung Cancer
Volume 47, Issue 1 , Pages 129-138 , January 2005

Article Tools

* Image Usage & Resolution